The effect of hospital-led prescribing on the cardiovascular budget of a fundholding general practice

Pharmaceutical Journal

Volumn 263, Issue 7059, 1999, Pages 292-294

  Edgar, Stephen ^a   Girvin, Briegeen ^b  

^a Pharmcare   (Ireland)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BISOPROLOL FUMARATE; CARDIOVASCULAR AGENT; ISOSORBIDE 5 NITRATE; NIFEDIPINE; PRAVASTATIN; SIMVASTATIN;

ARTICLE; BUDGET; DRUG CHOICE; DRUG COST; GENERAL PRACTICE; HOSPITAL CARE; HOSPITAL PHYSICIAN; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICAL AUDIT; MEDICAL RECORD; PRESCRIPTION; RETROSPECTIVE STUDY;

EID: 0033592250     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Walley T, Wilson R, Bligh J. Current prescribing in primary-care in the UK - effects of the indicative prescribing scheme and GP fundholding. Pharmacoeconomics 1995; 7:320-31.
2. McGavock H. Rational discussion as a guide to more cost-effective and scientific prescribing in general practice: 15 years of experience in Northern Ireland. In: Lochen M (editor). Rational pharmacotherapy in general practice. Berlin: Springer-Verlag, 1991:186-200.
3. Department of Health. Delivering the future - primary care for the 21st century. London: DoH, 1996.
4. Bevan B. PACT data: avoiding the pitfalls. Pharm J 1996;257:25-30.
5. Crump BJ, Panton R, Drummond MF, Marchment M, Hawkes RA. Transferring the costs of expensive treatments from secondary to primary care. BMJ 1995;310:509-12.
6. Leach RH. Managing use of expensive new drugs in the NHS. Pharm J 1998;260:173-6.
7. Department of Health. Purchasing and prescribing (EL[94]72). London: DoH, 1994.
8. Audit Commission. A prescription for improvement: towards more rational prescribing in general practice. London: HM Stationery Office, 1994.
9. Taylor R, Bond CM. Change in the established prescribing habits of general practitioners: an analysis of initial prescriptions in general practice. Br J Gen Pract 1991;41:244-8.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994;344:1383-9.
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
12. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Ibid 1996;335:1001-9.
13. Too many beta blockers. Drug Ther Bull 1996;34:49-52.
14. Sever P, Beevers G, Bulpitt C, Lever A, Reid J et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993;306:983-7.